title: A comparison of outcomes between OKT3 and antithymocyte globulin for treatment of steroid-resistant rejection in hepatitis C liver transplant recipients.
abstract: BACKGROUND
  The treatment of steroid-resistant rejection (SRR) is associated with severe recurrent hepatitis C virus (HCV) infection after liver transplantation (LTx). After OKT3 was recently withdrawn from the market, thymoglobulin (TG) became the principal treatment for SRR.
  
  
  METHODS
  A retrospective analysis of 32 HCV patients who were treated for SRR with OKT3 (n=15) or TG (n=17) using yearly protocol liver biopsies. Mean follow-up was 4.3 years (OKT3) and 3.2 years (TG). We compared both groups for patient survival, graft loss, and severity of HCV recurrence, manifested as the mean stage of fibrosis (MSF).
  
  
  RESULTS
  Patient survival at 1, 2, and 5 years after LTx was 80%, 73%, and 67% in the OKT3 group and 82%, 77%, and 64% in the TG group, respectively. At 2 years after LTx, the graft losses were 3 versus 4 in the OKT3 and TG groups, respectively. At years 1 and 2, the MSF in the OKT3 group was 1.9 and 2.3 versus 2.4 and 2.8 in the TG group, respectively. None of the differences between both groups was statistically significant.
  
  
  CONCLUSIONS
  There was no significant difference in patient survival, graft loss, or severity of recurrent HCV, measured as MSF, between both groups.
authors.affiliation: 1 Internal Medicine Department, Baylor University Medical Center, Dallas, TX. 2 Division of Gastroenterology, Internal Medicine Department, Baylor University Medical Center, Dallas, TX. 3 Address correspondence to: Mina M. Benjamin, M.D., Internal Medicine Department, Baylor University Medical Center, 3500 Gaston Avenue, Dallas, TX 75246.
authors.forename: Mina M
authors.initials: MM
authors.lastname: Benjamin
authors.forename: Kevin J
authors.initials: KJ
authors.lastname: Dasher
authors.forename: James F
authors.initials: JF
authors.lastname: Trotter
mesh_terms: D000328:Adult; D000368:Aged; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D001706:Biopsy; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy*; D006085:Graft Survival; D006526:Hepatitis C / Q000628:therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008099:Liver / Q000473:pathology; D016031:Liver Transplantation / Q000379:methods*; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D012008:Recurrence; D012189:Retrospective Studies; D013256:Steroids / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D013256:Steroids